Molecure S.A. (MOC.WA)

PLN 10.0

(-1.96%)

Market Cap (In PLN)

168.36 Million

Revenue (In PLN)

100.00

Net Income (In PLN)

-18.3 Million

Avg. Volume

14.35 Thousand

Currency
PLN
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
8.31-20.75
PE
-
EPS
-
Beta Value
2.202
ISIN
PLONCTH00011
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Marcin Jan Szumowski Ph.D.
Employee Count
-
Website
https://molecure.com
Ipo Date
2018-04-01
Details
Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. It is involved in the development of OATD-01, a chitotriosidase/acidic mammalian chitinase inhibitor that has completed phase I clinical trial for the treatment of idiopathic pulmonary fibrosis and sarcoidosis; YKL-40 program for the treatment of cancer and fibrosis; OATD-02 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022. Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland.